Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study
Many studies have evaluated the total lymphocyte count (TLC) as a cheap surrogate marker for CD4 cells in HIV‐infected patients not receiving antiretroviral therapy (ART). We assessed whether TLC can replace CD4 cell counts in evaluating the immunological response to ART. In a cohort of patients in Indonesia TLC, if measured after at least 1‐year ART, correctly identified patients with <200 CD4 cells, and reliably excluded immunological failure, obviating the need for CD4 cell measurement in 43% of patients.
Document Type: Research Article
Affiliations: 1: Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands 2: Internal Medicine Department at Medical Faculty, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia
Publication date: May 1, 2012